Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT06185556	TitleCOLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases	Fase Fase 2	Date Added 2023-12-29	Ubicación Países Bajos	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06176885	TitleEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	Fase Fase 2	Date Added 2023-12-20	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Camrelizumab	Etiquetas MSS/ MMRp
NCT ID NCT06152523	TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer	Fase Fase 2	Date Added 2023-11-30	Ubicación Francia	Prior IO Allowed No	CRC-directed Sí	Status Aún no se ha contratado	Drogas Monalizumab/MEDI5257	Etiquetas MSI-H/ MMRd
NCT ID NCT06149481	TitleEstudio de fase I/II del régimen de inmunoterapia combinada: SX-682, Vacuna TriAdeno, Retifanlimab y Agonista de IL-15 N-803 (STAR15) para el Cáncer Colorrectal Metastásico (CCRm).	Fase Phase 1, Phase 2	Date Added 2023-11-29	Ubicación Maryland, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas N-803, Retifanlimab, SX-682	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06120127	TitlePostoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence	Fase Fase 2	Date Added 2023-11-07	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Chemotherapy, PD-1 antibody	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06106308	TitleStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation	Fase Fase 2	Date Added 2023-10-30	Ubicación Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Bevacizumab, FOLFIRI, FOLFOX, Onvansertib	Etiquetas MSS/ MMRp
NCT ID NCT06107413	TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab	Fase Fase 2	Date Added 2023-10-30	Ubicación Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Bélgica Alemania Israel Japón Corea, República de España Taiwán	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan	Etiquetas MSS/ MMRp
NCT ID NCT06105021	TitlePhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor	Fase Phase 1, Phase 2	Date Added 2023-10-27	Ubicación California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas AFNT-211	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06102902	TitleTesting the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC	Fase Fase 1	Date Added 2023-10-26	Ubicación California, United States Kansas, United States Ohio, United States Oklahoma, United States Texas, United States Virginia, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas BET Bromodomain Inhibitor ZEN-3694, encorafenib	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT06099821	TitleKN046 más regorafenib o apatinib en cánceres del aparato digestivo MSI-H resistentes al bloqueo de PD-1/PD-L1	Fase Fase 2	Date Added 2023-10-25	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas apatinib, KN046, Regorafenib	Etiquetas MSI-H/ MMRd

Showing 31 to 40 of 299 entries